FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions (2023)

Government Record · U.S. Food and Drug Administration · May 11, 2023

FDA required class-wide boxed-warning language addressing misuse, abuse, addiction, and overdose for prescription stimulants. The communication also required related updates elsewhere in prescribing information.

We are requiring that the Boxed Warning information, our most prominent warning, describe these risks consistently across all prescription stimulants, and we are requiring updates to other sections of the prescribing information.

FDA required class-wide boxed-warning language addressing misuse, abuse, addiction, and overdose for prescription stimulants. The communication also required related updates elsewhere in prescribing information.

Election Day is Tuesday, Nov 3. Know who you're voting for: your values vs. their record, with sources.Build my Vote Card →